Roundup: Singapore approves VUNO's AI fundus analysis software and more

Roundup: Singapore approves VUNO’s AI fundus analysis software and more

Singapore authorizes VUNO’s AI software for fundus analysis

South Korean medical AI company VUNO recently obtained medical device certification from the Singapore Health Sciences Authority for its AI-based fundus analysis software.

The VUNO Med-Fundus AI analyzes images of the fundus, which is the back part of the eye, to provide the results needed to diagnose retinal diseases. It can detect the location of lesions indicative of diseases, such as diabetic retinopathy, macular disease and glaucoma, in seconds.

With this certification, VUNO can tap into the growing medical device market in Singapore, which is expected to reach $1 billion in value by 2024, growing at a CAGR of 8.7% from 2019.

Taiwanese company Point Robotics obtains 510(k) for its surgical robot system

Point Robotics, a surgical robot maker in Taiwan, has received 510(k) clearance from the U.S. Food and Drug Administration for its integrated robotic-assisted surgical system for spinal fusion surgeries.

The POINT Kinguide robot-assisted surgical system combines image-guided navigation and a hand-drill function to streamline procedural tasks with precision, stability, and repeatability of robot motion.

What sets it apart from similar systems, the company says, is the parallel manipulation mechanism that allows it to expand indications for more complicated disc decompression surgery.

Following US clearance, Point Robotics is preparing for CE marking in Europe and registration in China, expanding its presence in international markets.

“We aim to promote the availability and affordability of robot adoption for spinal surgery not treated by current technology to treat more patients who have contracted a range of spinal diseases,” said said CEO SC Juang.

Mental health startup Lissun receives $1 million in pre-seed funding

Indian mental health platform Lissun has raised $1 million in a pre-seed funding round led by IvyCap Ventures. The round was also participated by We Founder Circle, Supermorpheous and other high-profile angel investors.

The startup uses a unique “B2H2C” approach – it reaches consumers through its partnerships with healthcare institutions – offering its comprehensive mental health solution. It has links with over 70 healthcare organizations in 17 cities in India.

According to a press release, Lissun’s technology is being applied to high-stress use cases in six healthcare categories, such as infertility, rehabilitation, nephrology and oncology, among others. “The very fact that mental and emotional issues can be an underlying issue in many medical cases is what we have identified and are proactively working on,” explained co-founder Dr. Krishna Veer Singh. .

With its new investment, Lissun aims to strengthen the backbone of its technology and further develop it to deliver a seamless user experience. Additionally, it plans to expand to 25 cities, as well as cover five other therapeutic categories.

India to reuse COVID-19 apps

The Indian government plans to repurpose its two main mobile apps to track COVID-19 cases in the country.

A news the report quotes Dr. Ram Sewak Sharma, CEO of the National Health Authority, who said they plan to repurpose the Aarogya Setu contact tracing app as a national health app while the platform form Covid Vaccine Intelligent Network (CoWIN) will be reused for the national immunization program and a health management information system for small doctors.

Similar Posts